Provided are diaminopyrazine derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include 4-[N&rsquo-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-guanidinomethyl]-4-phenethyl-piperidine-1-carboxylic acid tert-butyl ester and 4-[N&rsquo-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-guanidinomethyl]-4-phenethyl-piperidine-1-carboxamidine . The compounds are inhibitors of epithelial sodium channels (ENaC). The compounds may be useful in the treatment of respiratory diseases such as cystic fibrosis.